More about

Severe Atopic Dermatitis

News
February 10, 2022
1 min read
Save

FDA grants priority review to Dupixent for atopic dermatitis patients 6 months to 5 years

The FDA has accepted for priority review a supplemental biologics application for Dupixent that could allow treatment of moderate to severe atopic dermatitis in patients aged 6 months to 5 years, Regeneron announced in a press release.

News
January 14, 2022
1 min read
Save

FDA approves Cibinqo for moderate to severe atopic dermatitis

The FDA approved cibinqo, an oral, once-daily JAK inhibitor, for the treatment of patients with moderate to severe atopic dermatitis, according to a press release.

News
September 10, 2021
1 min read
Save

Severe atopic dermatitis associated with depression, internalizing behaviors in children

Severe atopic dermatitis is associated with depression and internalizing behaviors in childhood and adolescence, according to a study.

News
September 01, 2021
1 min read
Save

Methotrexate, azathioprine show comparable safety, efficacy in pediatric atopic dermatitis

Methotrexate and azathioprine yielded similar risk-benefit ratios as first-line therapy for children with severe atopic dermatitis, according to a study.

News
August 27, 2021
1 min read
Save

Induction abrocitinib may prevent flare in moderate, severe atopic dermatitis

Induction therapy with abrocitinib was associated with low flare rates in patients with moderate to severe atopic dermatitis, according to a study.

News
March 23, 2020
2 min read
Save

Abrocitinib meets co-primary endpoints in phase 3 trial

The phase 3 JADE COMPARE trial met its co-primary efficacy endpoints in adults with moderate to severe atopic dermatitis. Results from the trial, which compared the use of the JAK1 inhibitor abrocitinib with placebo, will be submitted for presentation at a future conference, according to a press release from Pfizer.

News
January 31, 2020
2 min read
Save

Baricitinib achieves primary endpoint in BREEZE-AD4, BREEZE-AD5 studies

Eli Lilly and Company and Incyte announced that baricitinib met its primary endpoint in the BREEZE-AD4 and BREEZE-AD5 studies in patients with moderate to severe atopic dermatitis, according to two press releases.

News
August 07, 2019
1 min read
Save

Dupixent shows positive results in children with severe atopic dermatitis

Children aged 6 to 11 years with severe atopic dermatitis assigned dupilumab and topical corticosteroids significantly improved in measures of overall disease severity, skin clearing, itching and health-related quality of life vs. topical corticosteroids alone in a phase 3 trial.

View more